Government Affairs en Salud

Bibliografía*

PARTE I. CONTEXTO INSTITUCIONAL Y POLITICO
1. El sistema sanitario español y su evolución
JULIÁN GARCÍA-VARGAS

3. La relación del sistema sanitario español con la UE
CARLOS PARRY

4. Los stakeholders del sistema sanitario español
JOSÉ LUIS FERNÁNDEZ

PARTE II. LA VISIÓN Y EL ROL DE LOS STAKEHOLDERS
6. La visión desde el Ministerio de Sanidad
SALVADOR ILLA

10. La visión desde las consejerías de Salud autonómicas 1
BOI RUIZ

12. El rol de la corporación médica
TOMÁS COBO

13. El rol de la corporación farmacéutica
JESÚS AGUILAR

15. El rol de las sociedades científicas farmacéuticas 1
VICENTE J. BAIXAULI

16. El rol de las sociedades científicas farmacéuticas 2
JOSÉ MANUEL PAREDERO

  • Abughosh, S.M., Wang, X., Serna, O., Henges, C., Masilamani, S., Essien, E.J., et al. (2016). “A pharmacist telephone intervention to identify adherence barriers and improve adherence among nonadherent patients with comorbid hypertension and diabetes in a medicare advantage plan”. J Manag Care Spec Pharm. 2016 Jan; 22(1):63-73. doi: 10.18553/jmcp.2016. 22.1.63.
  • Arsoy, G., Varış, A, Saloumi, L.M., Abdi, A., Başgut, B. (2018). “Insights on allergic rhinitis management from a northern cyprus perspective and evaluation of the impact of pharmacist-led educational intervention on patients’ outcomes”. Medicina (Kaunas). 2018 Nov 7; 54(5). doi: 10.3390/medicina54050083.
  • Basaraba J.E., Picard, M., George-Phillips, K., Mysak, T. (2018). Pharmacists as care providers for stroke patients: a systematic review. Can J Neurol Sci. 2018 Jan;45(1):49-55. doi: 10.1017/cjn.2017.233.
  • Bingham, J., Axon, D.R., Scovis, N., Taylor, A.M. (2018). “Evaluating the effectiveness of clinical pharmacy consultations on nutrition, physical activity, and sleep in improving patient-reported psychiatric outcomes for individuals with mental illnesses”. Pharmacy (Basel). 2018 Dec 22;7(1). doi:10.3390/pharmacy7010002.
  • BOE (2029). Ley 3/2019, de 2 de julio, de ordenación farmacéutica de Galicia.
  • BOE (1986). Ley General de Sanidad 14/1986, de 25 de abril.
  • BOE (2015). Real Decreto Legislativo 1/2015, de 24 de julio.
  • Brody, A., Stewart, B., Zhang, L., Levy, P. (2018). “Can pharmacists effectively manage blood pressure for discharged urban emergency department patients with uncontrolled hypertension?” Ann Emerg Med. 2018 Oct; 72; 4:S36-7. doi. 10.1016/j.annemergmed. 2018.08.088.
  • Bukhsh, A., Tan, X.Y., Chan, K.G., Lee, L.H., Goh, B.H., Khan, T.M. (2018). “Effectiveness of pharmacist-led educational interventions on self-care activities and glycemic control of type 2 diabetes patients: a systematic review and meta-analysis”. Patient Preference and Adherence. 2018 Nov 21; 12:2457-2474. doi: 10.2147/PPA.S180256.
  • Bukhsh, A., Khan, T.M., Lee, S.W.H., Lee, L.H., Chan, K.G., Goh, B.H. (2018). “Efficacy of pharmacist-based diabetes educational interventions on clinical outcomes of adults with type 2 diabetes mellitus: a network meta-analysis”. Frontiers in Pharmacology. 2018 Apr 10;9:339. doi: 10.3389/fphar.2018.00339.
  • Cheong, J.Y.V., Hie, S.L., Koh, E.W., de Souza, N.N.A., Koh, M.J. (2019). Impact of pharmacists’ counseling on caregiver’s knowledge in the management of pediatric atopic dermatitis. Pediatr Dermatol. 2019 Jan; 36(1):105-109. doi: 10.1111/pde.13708.
  • AMA Ed Hub. (2017). Embedding pharmacist into the practice. Collaborate with pharmacist to improve patients outcome.
  • Dunn, S.P., Birtcher, K.K., Beavers C.J., Baker, W.L., Brouse, S.D. (2015). “The role of the clinical pharmacist in the care of patients with cardiovascular disease”. J Am Coll Cardiol. 2015 Nov 10; 66(19):2129-2139. doi:10.1016/j.jacc.2015.09.025.
  • Hazen, A.C.M., Zwart, D.L.M., Poldervaart, J.M., de Gier, J.J., de Wit, N.J., de Bont, A.A. et al. (2019). “Non-dispensing pharmacists’ actions and solutions of drug therapy problems among elderly polypharmacy patients in primary care”. Family Practice. 2019 Jan 10. doi:10.1093/fampra/cmy114.
  • Hesso, I., Gebara, S.N., Kayyali, R. (2016). “Impact of community pharmacists in COPD management: inhalation technique and medication adherence”. Respiratory Medicine. 2016 Sep; 118:22-30. doi:
  • 10.1016/j.rmed.2016.07.010.
  • Hou, K., Yang, H., Ye, Z., Wang Y., Liu, L., Cui, X. (2017). “Effectiveness of pharmacist-led anticoagulation management on clinical outcomes: a systematic review and meta-analysis”. J Pharm Pharm Sci. 2017; 20(1):378-396. doi: 10.18433/J3SQ0B.
  • Jones, C.D., Anthony, A., Klein, M.D., Shakowski, C., Smith, H.K., Go, A. et al. (2003). “The effect of a pharmacist-led multidisciplinary transitions-of-care pilot for patients at high risk of readmission”. J Am Pharm Assoc (2003). 2018 Sep – Oct; 58(5):554-560. doi: 10.1016/j.japh.2018.05.008.
  • Kulchaitanaroaj, P., Brooks, J.M., Chaiyakunapruk, N., Goedken, A.M., Chrischilles, E.A., Carter. B.L. (2017). “Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care”. J Hypertens. 2017 Jan; 35(1):178-187. doi: 10.1097/HJH.0000000000001126.
  • Lai, P.S., Chua SS, Chan, S.P. (2013). “Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis”. Int J Clin Pharm. 2013 Aug; 35 629-37. doi: 10.1007/s11096-013-9784-x.
  • Lowrie, R., Lloyd, S.M., McConnachie, A., Morrison, J. (2014). “A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care”. PLoS One. 2014 Nov 18;9 (11):e113370. doi: 10.1371/journal.pone.0113370.
  • Liu, V.C., Mohammad I, Deol BB, Balarezo A, Deng L, Garwood CL. (2018). “Post-discharge medication reconciliation: reduction in readmissions in a geriatric primary care clinic”. J Aging Health. 2018 Aug 30. doi: 10.1177/0898264318795571.
  • Maeng, D.D., Graham, J., Bogart, M., Hao, J., Wright, E.A. (2018). “Impact of a pharmacist-led diabetes management on outcomes, utilization, and cost”. Clinicoecon. Outcomes Res. 2018 Sep 24; 10: 551-562. doi: 10.2147/CEOR.S174595.
  • McKinley, D., Moye-Dickerson. P., Davis, S., Akil. A. (2018). “Impact of a pharmacist-led intervention on 30-day readmission and assessment of factors predictive of readmission in african american men with heart failure”. Am J Mens Health. 2018 Nov 28. doi: 10.1177/1557988318814295.
  • Mes, M.A., Katzer, C.B., Chan, A.H.Y., Wileman, V., Taylor, S.J.C., Horne, R. (2018). “Pharmacists and medication adherence in asthma: a systematic review and meta-analysis”. Eur Respir J. 2018 Aug 23;52(2). pii: 1800485. doi: 10.1183/13993003.00485-2018.
  • Milfred-LaForest, S.K., Gee, J.A., Pugacz, A.M., Piña, I.L., Hoover, D.M., Wenzell, R.C. et al. (2017). “Heart failure transitions of care: a pharmacist-led post-discharge pilot experience”. Prog Cardiovasc Dis. 2017 Sep – Oct; 60 (2):249-258. doi: 10.1016/j.pcad.2017.08.005.
  • Mikuls, T.R., Cheetham, T.C., Levy, G.D., Rashid, N., Kerimian, A., Low, K.J. et al. (2018). “Adherence and outcomes with urate-lowering therapy: a site-randomized trial”. Am J Med. 2018 Nov 29. doi: 10.1016/j.amjmed. 2018.11.011.
  • Milosavljevic, A., Aspden, T., Harrison, J. (2018). “Community pharmacist-led interventions and their impact on patients’ medication adherence and other health outcomes: a systematic review”. Int J Pharm Pract. 2018 Oct; 26(5):387-397. doi: 10.1111/ijpp.12462.
  • Moye, P.M., Chu, P.S., Pounds, T., Thurston, M.M. (2018). “Impact of a pharmacy team-led intervention program on the readmission rate of elderly patients with heart failure”. Am J Health Syst Pharm. 2018 Feb 15;75(4):183-190. doi: 10.2146/ajhp170256.
  • National Health Service. Primary Care Workforce Commission (2017). The future of primary care. Creating teams for tomorrow.
  • Nguyen, T., Nguyen, T.H., Nguyen, P.T., Tran, H.T., Nguyen, N.V., Nguyen, H.Q., et al. (2018). “Pharmacist-led intervention to enhance medication adherence in patients with acute coronary syndrome in Vietnam: a randomized controlled trial”. Front Pharmacol. 2018 Jun 21; 9:656. doi: 10.3389/fphar.2018.00656.
  • Omboni, S., Caserini, M. (2018). “Effectiveness of pharmacist’s intervention in the management of cardiovascular diseases”. Open Heart. 2018 Jan 3;5 (1):e000687. doi: 10.1136/openhrt-2017-000687.
  • Ottenbros, S., Teichert, M., de Groot. R., Griens, F., Sodihardjo, F., Wensing, M., et al. (2014). “Pharmacist-led intervention study to improve drug therapy in asthma and COPD patients”. Int J Clin Pharm. 2014 Apr; 36(2):336-44. doi: 10.1007/s11096-013-9887-4.
  • Park, S., Marcum, Z.A. (2018). “Interventions to improve medication adherence in older adults with cognitive impairment”. Consult Pharm. 2018 Jul 1; 33(7):382-385. doi:10.4140/TCP.n.2018.382.
  • Pousinho, S., Morgado, M., Falcão, A., Alves, G. (2016). “Pharmacist interventions in the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials”. J Manag Care Spec Pharm. 2016 May;22(5):493-515. doi: 10.18553/jmcp.2016.22.5.493.
  • Presley, B., Groot, W., Pavlova, M. (2018). “Pharmacy-led interventions to improve medication adherence among adults with diabetes: A systematic review and meta-analysis”. Res Social Adm Pharm. 2018 Oct 3. pii:S1551-7411(18)30224-9. doi:10.1016/j.sapharm.2018.09.021.
  • Ramsubeik, K., Ramrattan, L.A., Kaeley, G.S., Singh, J.A. (2018). “Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis”. Ther Adv Musculoskelet Dis. 2018 Nov 19;10 (12):235-252.doi: 10.1177/1759720X18807117.
  • Ruud, K.W., Rønningen, S.W., Faksvåg, P.K., Ariansen, H., Hovland, R. (2018). “Evaluation of a structured pharmacist-led inhalation technique assessment service for patients with asthma and COPD in Norwegian pharmacies”. Patient Educ Couns. 2018 Oct;101(10):1828-1837. doi: 10.1016/j.pec.2018.05.018.
  • Schumacher, C., Moaddab, G., Colbert, M., Kliethermes, M. A. (2018). “The effect of clinical pharmacists on readmission rates of heart failure patients in the
    accountable care environment”. J Manag Care Spec Pharm. 2018 Aug;24(8):795-799. doi: 10.18553/jmcp.2018.24.8.795.
  • SEFAP. (2015). Forjando el papel del farmacéutico de atención primaria en Inglaterra.
  • Services Australia. (2018). A Stronger Rural Health Strategy.
  • Sociedad Española de Farmacéuticos de Atención Primaria (2017). Cartera de Servicios del Farmacéutico de Atención Primaria.
  • Stanton-Robinson, C., Al-Jumaili, A.A., Jackson. A., Catney, C., Veach, S., Witry, M.J. (2003). “Evaluation of community pharmacist-provided telephone interventions to improve adherence to hypertension and diabetes medications”. J Am Pharm Assoc (2003). 2018 Jul – Aug; 58(4S): S120-S124. doi: 10.1016/j.japh.2018.04.030.
  • Tan, E.C., Stewart, K., Elliott, R.A., George, J. (2014). “Pharmacist services provided in general practice clinics: a systematic review and meta-analysis”. Res Social Adm Pharm. 2014 Jul-Aug;10(4):608-22. doi: 10.1016/j.sapharm.2013.08.006.
  • Tinelli, M., White, J., Manfrin, A. (2018). “Novel pharmacist-led intervention secures the minimally important difference (MID) in Asthma Control Test (ACT) score: better outcomes for patients and the healthcare provider”. BMJ Open Respir Res. 2018 Oct 14;5(1):e000322. doi: 10.1136/bmjresp-2018-000322.
  • van Driel, M.L., Morledge, M.D., Ulep, R., Shaffer, J.P., Davies, P., Deichmann, R. (2016). “Interventions to improve adherence to lipid-lowering medication”. Cochrane Database Syst Rev. 2016 Dec 21;12:CD004371. doi: 10.1002/14651858.CD004371.pub4.
  • Yu, J., Shah, B.M., Ip, E.J., Chan, J. A. (2013). “Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California”. J Manag Care Pharm. 2013 Mar; 19(2):102-14.
  • Wright, E.A., Graham, J.H., Maeng, D., Tusing, L., Zaleski, L., Martin, R., et al. (2019). “Reductions in 30-day readmission, mortality, and costs with inpatient-to-community pharmacist follow-up”. J Am Pharm Assoc. 2019. Mar-Apr; 59(2):178-186. doi: 10.1016/j.japh.2018. 11.005.

18. El rol de la sanidad privada
CARLOS RUS


19. El rol de la industria farmacéutica innovadora
JESÚS PONCE


20. El rol de las compañías biofarmacéuticas
ANA POLANCO


21. El rol de las compañías de genéricos
MAR FÁBREGAS

22. El rol de las compañías de autocuidado de la salud
ALBERTO BUENO


23. El rol de las empresas de tecnología sanitaria
MARGARITA ALFONSEL

25. El rol de las sociedades de pacientes españolas
JOAN MARIA MORROS

26. El rol de las sociedades de pacientes españolas
Mª DOLORS NAVARRO

27. El rol de las sociedades de pacientes europeas
MARÍA CAVALLER

29. El rol de los influencers
ÁLVARO FERNÁNDEZ

PARTE III. HERRAMIENTAS PARA LA INFLUENCIA
30. El interés general
JORGE VÁZQUEZ

31. El jefe de Gabinete
ALBERTO LAHOZ

32. Protocolo
ANNA MAS

33. Comunicación con los mass media
RAQUEL CAPELLAS

35. Gestión de crisis
ASUNCIÓN SORIANO

  • Benioff, M., Langley, M. (2020). Pionero (TrailBlazer). Empresa activa.
  • Soriano, A., Ortega, I. (2021). De los Zeta a los Silver. Plataforma editorial.
  • Stone, D., Patton, B., Heen, S. (1999). Difficult Conversations. Penguin.
  • Tzu, S. (2018). El arte de la guerra. Dojo Ediciones.
  • Villafañe, J. (2023). La Buena Reputación. Pirámide.

PARTE IV. El PLAN DE ACCIÓN PARA LA INFLUENCIA
36. Marco metodológico del plan de acción
DAVID ELVIRA

PARTE V. OTRAS PERSPECTIVAS
37. Enfermedades raras e irreversibles: diagnóstico y tratamiento
FEDERICO MAYOR ZARAGOZA

Pérez, B. (2021). 50 años de cribado neonatal: cómo afrontamos el futuro. Fundación Ramón Areces, Ed.

¡Please don't go!

Antes de irte, dinos qué necesitas. Clica aquí para enviarnos un mail. Queremos que sea tu libro de referencia.